npyy2 receptor

BIIE-0246 is a selective NPY2R antagonist with an IC50 of 15 nM at the rat [125I]PYY3-36 site. It reduces NPY-stimulated expression of p-AKT S473 and P-p44/42 MAPK.

Pancreatic Polypeptide, rat acetate is an agonist of NPY receptor, with high affinity at NPYR4.

SF 11 is a potent, brain-penetrant neuropeptide Y Y2 receptor antagonist with an IC50 of 199 nM, exhibiting antidepressant-like activity.

CYM 9484 is a selective and potent neuropeptide Y (NPY) Y2 receptor antagonist with an IC50 value of 19 nM.

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY that acts as a potent and selective Y1 receptor agonist, with a dissociation constant (KD) of 1.0 nM [1].

"(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1]."

GEP44 is a peptide-biased triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), neuropeptide Y1 receptor (Y1-R), and neuropeptide Y2 receptor (Y2-R). It induces GLP-1R-dependent insulin secretion in rat and human islets by offsetting the actions of Y1-R and GLP-1R agonism, controlled by Y1-R antagonists. Additionally, GEP44 enhances glucose uptake in muscle tissue through Y1-R mediation independent of insulin and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 is utilized in studies related to obesity and type 2 diabetes.